医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BioCision to Develop Customized ThawSTAR Automated Cell Thawing System for Celgene Cellular Therapeutics

2015年06月01日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN RAFAEL, Calif.

BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, today announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision’s proprietary ThawSTAR™ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

Conventional thawing methods, including swirling vials in warm water baths or rolling vials between hands can result in variable cell viabilities and can increase contamination concerns. BioCision’s ThawSTAR system utilizes a patent pending adaptive sensing technology that incorporates algorithms to deliver a consistent and reproducible thaw profile and endpoint to each vial, thus providing a standardized thawing process, eliminating variability that could have a detrimental effect on the safety and efficacy of the cell therapy, and providing a significant reduction in cell handling risk in a clinical setting.

Dr. Rolf O. Ehrhardt, CEO of BioCision, said, “As more cell therapies reach late stage clinical trials and commercialization, the need to standardize and de-risk cell handling, including thawing, is becoming critical. The ThawSTAR system has been demonstrated to significantly improve cell viability and recovery in comparison to conventional methods, and may ultimately enhance the consistency of therapeutic outcomes.”

The new ThawSTAR automated cell thawing system that will be developed as a result of this collaboration is an expansion of BioCision’s technology platform and will be made available commercially. BioCision is also developing other vial formats to address the needs of the larger cell therapy market.

About BioCision, LLC

BioCision is a life science research and development company that develops products and solutions for process standardization throughout the healthcare industry through the application of advanced thermal regulation principles and technologies. The intuitive design and interconnectivity of BioCision products enables researchers, clinicians and manufacturers to protect the integrity of temperature-sensitive therapeutics, biological samples, and biomaterials. By addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development and enable effective care delivery.

For more information visit www.biocision.com, or visit the BioCision blog for news and expert insight at http://blog.biocision.com/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150601005321/en/

CONTACT

BioCision
Marla Kertzman, 209-852-9027
mkertzman@biocision.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆